Cargando…

Toxicity Study of Streptococcus pneumoniae Vaccine Administrated Subcutaneously in Rats

This study was performed to evaluate the toxicity of polysaccharide-based Streptococcus pneumoniae vaccine in Specific Pathogen Free (SPF), Sprague-Dawley (SD) rats. S. pneumoniae vaccine was administrated subcutaneously each dose level of high (560 μg/rat), medium (280 μg/rat) and low (140 μg/rat)...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sin Jeong, Seo, Kook Heon, Han, Sang In
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Toxicology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834373/
https://www.ncbi.nlm.nih.gov/pubmed/24278559
http://dx.doi.org/10.5487/TR.2011.27.2.111
Descripción
Sumario:This study was performed to evaluate the toxicity of polysaccharide-based Streptococcus pneumoniae vaccine in Specific Pathogen Free (SPF), Sprague-Dawley (SD) rats. S. pneumoniae vaccine was administrated subcutaneously each dose level of high (560 μg/rat), medium (280 μg/rat) and low (140 μg/rat) on days 0, 14, 28. The rats were observed for 2 weeks or 4 weeks after the final injection. During this test, there were no significant dose-dependent changes in body weight, water and food consumption. In urinalysis and serum chemistry, dose-related changes were not detected. In hematology, the percent of neutrophils and lymphocytes in white blood cells were changed significantly. According to the measurement of organ weight, only spleen weight was significantly increased in all groups of administration compared to the control group. In the histopathological examination, an antigen-deposit, vacuolated macrophages, infiltrated inflammatory cells and a formation of granulation tissue were observed at the site of an administration. These results are considered as an outcome by immune responses through a vaccination. Consequently, the results of this study demonstrated that S. pneumoniae vaccine has no toxicity when it was administrated subcutaneously three times in 2-week interval at a high dose of 560 μg/rat.